secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2025-11-18T23:59:59+00:00
Accession:  0001193125-25-285259
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks shifts to royalty-driven model, authorizes $125M buyback; appoints Platshon as CIO
--------------------------------------------------------------------------------

- Eligible for up to $440M in near-term milestones from Ziihera GEA approvals ($250M US, $100M EU, $75M Japan, $15M China).
- Board authorized $125M share repurchase program; prior $60M buyback retired ~4.4M shares (6% of outstanding).
- Cash and investments $299.4M as of Sep 30, 2025; with milestones expects to fund operations beyond 2028.
- Scott Platshon stepped down from board, appointed Acting CIO to manage healthcare asset aggregation strategy.
- Also eligible for up to $434M in additional milestones from J&J for pasritamig Phase 3 program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000119312525285259/0001193125-25-285259-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000119312525285259/d851143d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-285259

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer